CGTRepairing MS-caused damage with stem cellsBritish and Italian researchers have demostrated promising results in patients with progressive multiple sclerosis through stem cell transplantation into the brain. more ➔
COPDBreakthrough in COPD treatmentFrench Sanofi SA’s second Phase III trial of duplimab demonstrated a 34% reduction in exacerbations and significant lung function improvements. more ➔
ObesityNovo Nordisk invests €2.1bn in production expansionIn the race for global market share of its obesity and diabetes blockbuster semaglutide, Novo Nordisk is expanding production in Europe. more ➔
financingQuotient Therapeutics kicks-off with US$50m financingFlagship Pioneering has committed US$50m to launch Quotient Therapeutics that links genetic variation at cellular level with disease by Nanoseq, a sequencing method licenced from the Wellcome Sanger … more ➔
financingSolar Foods raises €8m in Series B financingFinnish protein maker Solar Foods has closed an oversubscribed €8M Series B financing and will expand Solein protein production and support the construction of a commercial production plant. more ➔
Novel FoodGermany boosts protein transition with €38mThe Budget Committee of the German Bundestag has announced to channel €38m in funding into the sustainable protein transition next year. more ➔
Novel FoodMicroharvest GmbH launches SCP-Pilot plant in LissabonGerman precision fermentation specialist MicroHarvest GmbH has launched a single-cell protein pilot plant in Lison with an initial capacity of 25kg per day. more ➔
AMR partnershipAMR: Partnership set to improve in vivo antibiotics testingThe Innovative Medicine Initiative 2 JU-funded €25m project COMBINE is joining forces with CARB-X & CAIRD, iiCON and Pharmacology Discovery Services to improve in vivo antibiotics testin … more ➔
financingVectorY Therapeutics raises €129m in Series A roundDutch VectorY Tx BV has closed one of this yers’s largest Series A financing rounds in Europe at €129m to push its vecorised antibody pipeline in CNS proteinopathies. more ➔
financingViaNautis Bio Ltd closes US$25m Series A financingIntracelluar drug delivery specialist ViaNautis Bio Ltd will use US$25 raised in a Series A financing to push applications of its bionic nanoparticle platform polyNaut. more ➔
